Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets

Heart Failure Clinical Trial

Official title:

Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02522208
• Other study ID #: AR06.009
• Status: Completed
• Phase: Phase 1
• First received: August 5, 2015
• Last updated: November 7, 2016
• Start date: September 2015
• Est. completion date: April 2016

Study information

• Verified date: November 2016
• Source: Arbor Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.

Description:

A multiple-center, open-label, randomized, daily dose, two-sequence, two-way crossover pharmacodynamics (PD) and pharmacokinetic (PK) study of BiDil XR capsules and commercial BiDil tablets in Self-identified Black Patients, who are Slow Acetylators, with Heart Failure and have not received BiDil, isosorbide dinitrate (ISDN), or hydralazine hydrochloride (HCl) for at least 30 days prior to screening. The study consists of two doses of BiDil XR capsules (dosed at 0 hr and 9 hr) and three doses of BiDil tablets (dosed at 0 hr, 6 hr and 12 hr).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Self-identified Black, stable, chronic heart failure male or female subjects classified as having New York Heart Association (NYHA) Class II or III, diagnosed at least 3 months prior to Screening.

• Clinically stable outpatient, receiving standard, stable treatment regimen for heart failure (HF), at least 2 weeks prior to screening and throughout the duration of the trial. Subjects receiving beta-blockers must have been taking these for at least 3 months.

• All other medications must have been at a stable dose for at least 2 weeks prior to first dose

• Subjects must not have received BiDil, isosorbide dinitrate or hydralazine HCl for at least 30 days prior to Screening

• Have an adequate and demonstrable baseline Tricuspid regurgitation jet, visible inferior vena cava, and adequate right heart echocardiogram (with or without saline bubble contrast) allowing measurements to be made.

• Baseline PA systolic pressures > 35 mmHg

• Slow acetylator

• Adult subjects at least 18 years old or state-specific age of majority.

• Clinical lab tests negative for HIV, Hepatitis B surface antigen and Hepatitis C antibody.

• Urine testing negative for alcohol and drugs of abuse.

• Negative human chorionic gonadotropin (hCG) pregnancy test.

• Females must agree to avoid becoming pregnant or males must agree to use appropriate contraceptive methods with his partner(s), during the study and up to post 30 days from last dose of study drug.

• Females must be:

• unable to have children or

• where the partner is sterile OR

• willing to remain abstinent OR

• willing to use two effective methods of birth control.

• Willing and able to be confined for inpatient study periods and agree to study restrictions

• Ability to grant voluntary informed consent to participate in the study.

Exclusion Criteria:

• Have significant valvular heart disease, hemodynamically significant obstructive hypertrophic cardiomyopathy, active myocarditis, or uncontrolled hypertension.

• Presence of severe, clinical right heart failure.

• Symptoms of unstable angina, a myocardial infarction, cardiac surgery, or percutaneous coronary intervention within 1 month prior to Screening

• Have coronary artery disease likely to require coronary artery bypass grafting or percutaneous coronary intervention during the ensuing 3 months.

• Had cardiac arrest or a sustained ventricular tachycardia considered life threatening and requiring intervention within 3 months, unless treated with implantable cardioverter-defibrillator.

• other causes of pulmonary hypertension that may confound pharmacodynamic assessments of heart failure

• Active malignancy or any non-cardiac life-limiting disease.

• Have significant hepatic, renal, or other disease that might confound the study results or present a risk to the subject.

• Had a stroke within the past 3 months.

• Received parenteral inotropic therapy within 1 month.

• Likelihood of undergoing cardiac transplantation or circulatory assist device implant over the ensuing 3 months.

• Symptomatic hypotension or blood pressure less than 110/70 mmHg at Screening.

• Any condition or risk factor which would jeopardize the evaluation of efficacy or safety or the ability to obtain effective echocardiography results.

• Currently require riociguat, hydralazine HCl, long-acting nitrates like ISDN, isosorbide mononitrate or sustained release nitroglycerin or phosphodiesterase 5 inhibitors.

• Alcohol or drug abuse within 1 year of study participation.

• Hypersensitivity, allergy, idiosyncratic reaction or adverse reaction to caffeine (if slow acetylator test is required), ISDN, hydralazine HCl, or any compounds with similar chemical characteristics.

• Received investigational drug within 30 days.

• Donated one pint or more of blood, plasma, or platelets within 30 days.

• Any subject who, in the opinion of the Investigator, cannot follow instructions.

• Pregnant, lactating or plan to get pregnant during the study

• History of lupus erythematous or lupus like syndrome.

• Use of herbal preparations, grapefruit, grapefruit juice, Seville oranges/juice or use of phosphodiesterase inhibitors within 2 weeks of first dose of study drug and throughout study.

• Employee of the Sponsor, investigative site or contract research organization.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• BiDil XR
fixed combination capsule
• BiDil Immediate Release (IR)
fixed combination tablet

Locations

Country	Name	City	State
United States	Pinnacle Research Group, LLC	Anniston	Alabama
United States	Morehouse School of Medicine	Atlanta	Georgia
United States	Linfritz Research Institue Inc	Coral Gables	Florida
United States	Jacksonville Center for Clinical Research	Jacksonville	Florida
United States	Center for Medical Research, LLC	Providence	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Arbor Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Treatment effect on ejection fraction	assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure	6 days	No
Other	Treatment effect on Mean PA pressure	assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure	6 days	No
Other	Treatment effect on PA diastolic pressure	assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure	6 days	No
Other	Treatment effect on Pulmonary vascular resistance	assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure	6 days	No
Other	Treatment effect on Right atrial pressure	assessing the treatment effect of BiDil and BiDil XR on other central hemodynamic measures (such as ejection fraction) and examining the relationship between the plasma or blood concentrations of each treatment group and each of these central hemodynamic measure	6 days	No
Other	Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability	to compare the safety and tolerability of BiDil XR capsules, as measured by treatment-emergent AEs	12 days	Yes
Primary	Pulmonary Artery (PA) Systolic Pressure change from baseline to each post dose timepoint for 28 hours	assess the treatment effect of BiDil and BiDil XR on Pulmonary Artery Systolic Pressure (PASP) by Doppler echocardiography	6 days	No
Secondary	Comparison of Maximum observed effect (Emax) on PA systolic pressure vs maximum blood concentration (Cmax)	examine the relationship between the blood concentrations of each active treatment group and the changes in PASP	6 days	No
Secondary	Comparison of the area under the effect curve (AUEC) on PA systolic pressure versus AUC (the area under the curve) for blood	To examine the relationship between the blood concentrations of each active treatment group and the changes in PASP	6 days	No